Cutting-Edge Science Our Science ↓ How We Finish Fibrosis We are on a quest to break new ground in fibrosis treatment through scientific discovery. Applying our extensive expertise in integrin and fibrosis biology, we have our sights set on creating groundbreaking new therapies for fibrosis and fibrosis-related diseases. Our Path Fibrosis is caused when cells that normally repair tissue through scar formation become dysregulated, or out of control. This dysregulation causes the cells to create and deposit excessive collagen in the affected organs, a process known as fibrosis. Fibrosis replaces healthy tissue with scar tissue in vital organs, causing irreparable damage and eventual organ failure. Our Approach Your browser does not support the video tag. The Role of Integrins in Fibrosis Your browser does not support the video tag. The TGF-β Fibrosis Cascade Your browser does not support the video tag. PLN-74809 – Pliant’s Tissue-Specific Approach to Treating Fibrosis Our Difference Transforming growth factor beta, or TGF-β, is a key driver of fibrosis. A number of investigational therapies for fibrotic and other diseases systemically block TGF-β, risking toxicity to a patient’s unaffected organs due to TGF-β’s many important roles in healthy tissues. At Pliant, our focus is on using tissue-specific integrin targets to block TGF-β only in affected organs, with the goal of reducing side effects. Our Advanced Integrin Library We have developed an industry-leading library of over 9,500 annotated integrin binding molecules to probe the molecular drivers of fibrotic disease. This library enables the screening of newly identified targets to create a deep well of potential drug candidates. Our Limitless Possibilities Currently, our proprietary capabilities include a target expression atlas, an expansive library of over 9,500 integrin binding molecules, integrin screening assay platform, live fibrotic human tissue assay program, PET ligand imaging program, and biomarker assays. We continue to expand our integrin inhibitor library and develop tools, such as additional PET ligands as well as novel disease biomarkers. In addition, we have a searchable library of over 70,000 compounds for non-integrin targets. Our Pipeline Our Pipeline Our highly experienced team of fibrosis and drug development experts are claiming new territory in tissue-specific therapies. Pliant's broad pipeline includes two clinical stage programs, including the first clinical stage, oral, selective small molecule integrin inhibitor, PLN-74809. Learn More → PLN-74809 for IPF and PSC → PLN-1474 NASH → Oncology → Muscular Dystrophy → Publications & Posters Our Publications Our team has unmatched expertise in fibrosis and integrin biology and we value sharing our knowledge. We regularly publish and present our research in a variety of forums to advance the discovery of novel targeted therapies to finish fibrosis. Read our most recent publications below. Read All Publications → Most Recent Publications Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF → TGF-β as a driver of fibrosis: physiological roles and therapeutic opportunities → Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness → Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations → The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis → Our Patients Our lead product candidate, PLN-74809, is an investigational oral treatment for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). We are currently recruiting Phase 2a clinical trials in both IPF and PSC. Learn about our clinical trials. Learn More → About Our Science Pipeline Patients Investors & Media Careers Contact Terms of Use Privacy Notice CCPA Applicant and Staff Privacy Notice Copyright © 2021 Pliant Therapeutics, Inc. | All Rights Reserved